TY - JOUR
T1 - Rapid in vivo metabolism of a methylether derivative of (±)-BW373U86
T2 - The metabolic fate of [3H]SNC121 in rats
AU - Schetz, John A.
AU - Calderon, Silvia N.
AU - Bertha, Craig M.
AU - Rice, Kenner
AU - Porreca, Frank
PY - 1996/12
Y1 - 1996/12
N2 - Activation of opioid delta receptors produces antinociceptlon without some of the side-effects associated with activation of mu and kappa receptors. (±)-BW373U86 {(±)-4-[(α-R″)-α((2S″,5R″)-4-allyl-2,5- dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide} is a first generation, racemic nonpeptide, partially delta-selective opioid agonist that produces short-lived antinocioception. After systemic, but not central, administration, (±)-BW373U86 is also a naltrindole-reversible convulsant. SNC80 {(±)-4-[9-α-R)-α-((2S,5RO-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide} is a chiral methylether derivative of (±)-BW373U86 with decreased potency, but greater selectivity for the delta- opioid receptor. Like BW373U86, SNC80 produces brief, nonlethal seizures when administered peripherally, albeit at higher doses. Radiolabeling of SNC80 yields a compound with similar pharmacology named [3H]SNC121. [3H]SNC121 was investigated to determine the relationship between its time course of metabolism and the physiological actions of SNC80. The biotransformation of i.p. administered [3H]SNC121 was established in rats in vivo and in vitro via high-performance liquid chromatography analysis of extracted radioactive tissues and fluids. Radioactive equivalents were characterized by their high- performance liquid chromatography retention times and opioid binding activity in rat brain membranes. The kidney, and especially the liver (within 5 min), rapidly metabolize SNC121 to a metabolite with delta-opioid activity coeluting with BW373U86. Direct i.c.v. administration of [3H]SNC121 resulted in minimal metabolism after 1 hr. We conclude that i.p., but not i.c.v., administered [3H]SNC121 can be metabolized rapidly and substantially by the liver to a BW373U86-like compound. The in vivo time course of metabolism after i.p. administration of [3H]SNC121 is consistent with the duration of SNC80 antinociception, and the rapid formation of a BW373U86-like metabolite may also account, in part, for its convulsant properties.
AB - Activation of opioid delta receptors produces antinociceptlon without some of the side-effects associated with activation of mu and kappa receptors. (±)-BW373U86 {(±)-4-[(α-R″)-α((2S″,5R″)-4-allyl-2,5- dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N,N-diethylbenzamide} is a first generation, racemic nonpeptide, partially delta-selective opioid agonist that produces short-lived antinocioception. After systemic, but not central, administration, (±)-BW373U86 is also a naltrindole-reversible convulsant. SNC80 {(±)-4-[9-α-R)-α-((2S,5RO-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide} is a chiral methylether derivative of (±)-BW373U86 with decreased potency, but greater selectivity for the delta- opioid receptor. Like BW373U86, SNC80 produces brief, nonlethal seizures when administered peripherally, albeit at higher doses. Radiolabeling of SNC80 yields a compound with similar pharmacology named [3H]SNC121. [3H]SNC121 was investigated to determine the relationship between its time course of metabolism and the physiological actions of SNC80. The biotransformation of i.p. administered [3H]SNC121 was established in rats in vivo and in vitro via high-performance liquid chromatography analysis of extracted radioactive tissues and fluids. Radioactive equivalents were characterized by their high- performance liquid chromatography retention times and opioid binding activity in rat brain membranes. The kidney, and especially the liver (within 5 min), rapidly metabolize SNC121 to a metabolite with delta-opioid activity coeluting with BW373U86. Direct i.c.v. administration of [3H]SNC121 resulted in minimal metabolism after 1 hr. We conclude that i.p., but not i.c.v., administered [3H]SNC121 can be metabolized rapidly and substantially by the liver to a BW373U86-like compound. The in vivo time course of metabolism after i.p. administration of [3H]SNC121 is consistent with the duration of SNC80 antinociception, and the rapid formation of a BW373U86-like metabolite may also account, in part, for its convulsant properties.
UR - http://www.scopus.com/inward/record.url?scp=0030432232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030432232&partnerID=8YFLogxK
M3 - Article
C2 - 8968326
AN - SCOPUS:0030432232
SN - 0022-3565
VL - 279
SP - 1069
EP - 1076
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
IS - 3
ER -